AstraZeneca offloads ciclesonide rights to Covis in $350m deal
6th Dec 2018 07:23
(Sharecast News) - AstraZeneca has completed an agreement with Covis Pharma to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis.
Read moreAstraZeneca offloads rights to Nexium and Vimovo
3rd Dec 2018 07:25
(Sharecast News) - AstraZeneca has completed an agreement to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights - excluding the US and Japan - to Vimovo (naproxen/esomeprazole), to Grunenthal, it announced on Monday.
Read moreUS FDA grants orphan status for AstraZeneca's Fasenra
26th Nov 2018 07:18
(Sharecast News) - AstraZeneca on Monday said its Fasenra treatment for the autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA) had been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA).
Read moreMonday broker round-up
19th Nov 2018 12:13
(Sharecast News) - Sainsbury: Berenberg reiterates buy with a target price of 369p.
Read moreBP, Astra, NMC, Lloyds among Barclays' European top picks
19th Nov 2018 08:52
(Sharecast News) - Although poor investor sentiment, "idiosyncratic risks" including Brexit, Italian and German politics, ECB and European parliamentary elections next year have weighed on European stock, Barclays expects to see some of the losses to be recouped into the year end, with 19 selected as "top picks".
Read moreAstraZeneca offloading rights to two non-core drugs
30th Oct 2018 07:12
(Sharecast News) - AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights - excluding the US and Japan - to Vimovo (naproxen/esomeprazole), to Grünenthal, it announced on Tuesday.
Read moreTuesday broker round-up
23rd Oct 2018 12:53
(Sharecast News) - CYBG: Barclays initiates underweight with a target price of 280p.
Read moreAstraZeneca extends collaboration deal with Innate Pharma
23rd Oct 2018 07:19
(Sharecast News) - AstraZeneca, along with its global biologics research and development arm MedImmune, announced a new multi-term agreement with Innate Pharma on Tuesday, building on an existing collaboration.
Read moreMonday broker round-up
22nd Oct 2018 12:35
(Sharecast News) - British Land: Credit Suisse downgrades to underperform with a target price of 620p.
Read moreAstraZeneca gets positive opinion for COPD treatment
19th Oct 2018 07:50
(Sharecast News) - AstraZeneca received a thumbs-up from European regulators about its metered-dose inhaler to treat chronic obstructive pulmonary disease.
Read moreAstraZeneca and Merck get designation for Lynparza in pancreatic cancer
16th Oct 2018 08:03
(Sharecast News) - AstraZeneca, alongside Merck & Co, announced on Tuesday that the two parties have been granted orphan drug designation (ODD) by the US Food and Drug Administration for Lynparza (olaparib) for the treatment of pancreatic cancer.
Read moreMonday broker round-up
8th Oct 2018 13:07
(Sharecast News) - Mediclinic International: Investec upgrades to buy with a target price of 448p.
Read moreAstraZeneca drug cuts lung cancer deaths by nearly a third
25th Sep 2018 16:25
(Sharecast News) - A clinical study has shown AstraZeneca's immunotherapy drug Imfinzi to have reduced the risk of death in patients with mid-stage lung cancer by nearly a third in a clinical study.
Read moreTuesday broker round-up
25th Sep 2018 12:57
(Sharecast News) - Wetherspoons: Peel Hunt downgrades to hold with a target price of 1,325p.
Read moreMonday broker round-up
24th Sep 2018 12:59
(Sharecast News) - Thomas Cook: Shore Capital Markets downgrades to hold.
Read more